Belite Bio, Inc (BLTE)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $148.72
- As of
Kresmion compiles this page from BLTE's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
BELITE BIO, INC (BLTE): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 6-K filed 2026-10-19.
See the full BLTE dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for BLTE on one page. Preview it with sample data, then open it live with a free account.
Preview the BLTE dossierActive events for BLTE
- highInsider cluster: sales
2 insiders at BLTE sold $8.6M this week
- highInsider cluster: sales
2 insiders at BLTE sold $31.9M this week
- mediumEarnings above estimates
Q2-2026: Beat consensus by 13.0%, EPS $-0.70 vs $-0.8045 estimate
- high13F: large increase
CITADEL ADVISORS LLC added +3583% to BLTE (2026Q2)
- high13F: large reduction
Point72 Asset Management, L.P. cut 82% of BLTE (2026Q2)
FREE, NO ACCOUNT
Every event on BLTE, as it fires
You are seeing 5 of 10 events recorded on BLTE since 2026-05-29.
The five above landed across 4 days. The other 5 were recorded on 2 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in BLTE (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 07782B104 · 2026Q2 | $76.2M | 0.03% | , |
| CITADEL ADVISORS LLCCUSIP 07782B104 · 2026Q2 | $28.7M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 07782B104 · 2026Q2 | $8.6M | 0.01% | , |
| Point72 Asset Management, L.P.CUSIP 07782B104 · 2026Q2 | $7.9M | 0.01% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 07782B104 · 2026Q2 | $5.9M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, BLTE
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 20-FSEC EDGAR ↗
- 6-KSEC EDGAR ↗
BLTE against its peers
BLTE's return on equity of -10.1% ranks in the 80th percentile of 22 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-03-31.
| Metric | BLTE | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 227M | n/a | 16 |
| Gross margin | n/a | 89.7% | n/a | 5 |
| Operating margin | n/a | -70.8% | n/a | 14 |
| Net margin | n/a | -72.0% | n/a | 14 |
| Return on equity | -10.1% | -36.0% | 80 | 22 |
Peers (24): MANE, IMVT, KOD, CNTA.D, CGON, RYTM, ORKA, LGND, COGT, MIRM, IOVA, ERAS, SRRK, PTCT, APLS.D, CRSP, DFTX, GRAL, IONS, TVTX, ALKS, ABVX, PRAX, DNTH. Left out: BCHMY (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (BLTE: 20-F), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow BLTE on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to BLTE for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.